Beijing VDJBio Co Ltd
-
VDJBio completes Series C financing and promotes clinical development of IL-6R antibodies
On June 5th, Beijing VDJBio Co., Ltd.(VDJBio) announced the completion of its Series C financing round.VDJ-001 is a recombinant humanized monoclonal antibody injection that targets interleukin-6 (IL-6) receptors.
